Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
HemodiafiltrationSepsisAcute Kidney Injury
Interventions
DEVICE

Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)

CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).

DRUG

Antibiotics

Antibiotic concentration-time data will be collected and analyzed.

Trial Locations (1)

Unknown

Helena Colom Codina, Barcelona

All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Hospital Universitari de Bellvitge

OTHER

NCT04033029 - Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®) | Biotech Hunter | Biotech Hunter